naion and glp 1 Andrew Lee, MD Smaller NAION Risk with Semaglutide

G.StratigouT.TsagarakisS

Decisions about continuing, pausing, or stopping Tesamorelin should be based on physician evaluation rather than information found on social media or online discussion boards

GIP(330)NH2 is a potent competitive antagonist of the GIP receptor and effectively inhibits GIP-mediated insulin, glucagon, and somatostatin release

In contrast to earlier GLP-1 receptor agonists, which primarily target appetite suppression and glycemic improvement, GLP-3 leverages GCG receptor activation to stimulate lipolysis and elevate basal metabolic rate, thereby contributing to a more pronounced and sustained reduction in adiposity as observed in research models